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Abstract
Summary The Indian Society for Bone and Mineral Research (ISBMR) has herein drafted clinical practice guidelines for
the diagnosis and management of osteoporosis for the people of India. Implementation of the position statement in clinical
practice is expected to improve the overall care of patients with osteoporosis in India.
Purpose In India, osteoporosis is a major public health problem. However, in the absence of any robust regional guidelines,
the screening, treatment, and follow-up of patients with osteoporosis are lagging behind in the country.
Methods The Indian Society for Bone and Mineral Research (ISBMR), which is a multidisciplinary group of physicians,
researchers, dietitians, and epidemiologists and who study bone and related tissues, in their annual meeting, drafted the guidelines for the diagnosis and management of osteoporosis that would be appropriate in a resource constraint setting like India.
Results Diagnosis of osteoporosis can be made in a patient with minimal trauma fracture without the aid of any other diagnostic tools. In others, bone mineral density measured by dual-energy X-ray absorptiometry remains the modality of choice.
Data indicates that osteoporotic fractures occur at an earlier age in Indians than in the West; hence, screening for osteoporosis
should begin at an earlier age. FRAX can be used for fracture risk estimation; however, it may underestimate the risk of future
fractures in our population and still needs validation. Maintaining optimum serum 25-hydroxyvitamin D levels is essential,
which, in most cases, would require regular vitamin D supplementation. Pharmacotherapy should be guided by the presence/
absence of vertebral/hip fractures or the severity of risk based on clinical factors, although bisphosphonates remain the first
choice in most cases. Regular follow-up is essential to ensure adherence and response to therapy.
Conclusions Implementation of the position statement in clinical practice is expected to improve the overall care of patients
with osteoporosis in India.
Keywords Osteoporosis · Fracture prevention · Guidelines · ISBMR · India

Introduction
Osteoporosis is a condition characterized by low bone mass
and micro-architectural deterioration of bone tissue, with a
consequent increase in bone fragility and susceptibility to
fracture. Osteoporosis increases the risk of incident fragility
fractures. Fragility fractures are a major health concern that
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contribute significantly to morbidity and increased mortality.
As the population worldwide is aging, a significant increase
in the incidence of osteoporosis is expected. Approximately
30% of all postmenopausal women have osteoporosis in the
USA and Europe. At least 40% of these women and 15–30%
of men will sustain one or more fragility fractures within
their remaining lifetime. In other words, 1 in 3 women over
age 50 will experience osteoporotic fractures, as will 1 in 5
men over age 50 [1, 2]. Despite marked advances in diagnosis and treatment for osteoporosis, very few patients receive
appropriate treatment, even after a fragility fracture [3].
India is home to more than 1.3 billion people, with
approximately 230 million Indians over 50 years. Most data
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on the prevalence of osteoporosis among women in India
come from studies conducted in small groups spread across
the country, and estimates from 2015 have suggested that
20% of the 230 million Indian women over age 50 have
osteoporosis [4, 5]. Prevalence of osteoporosis ranging
from 8 to 62% in Indian women of different age groups has
been reported in several studies [6–14]. The prevalence of
osteoporosis in males older than 50 years is also variable,
ranging from 8.5 to 24.6% [9, 15, 16]. A 2001 study in expatriate Indians in Singapore showed that the incidence of hip
fracture in the Indian population was 361 for women and
128 for men per 1,00,000 population. Extrapolating these
observations for the current Indian population as a whole,
the number of hip fractures every year would be more than
440,000, with a female to male ratio of about 3:1, with a
projected incidence of more than 600,000 in 2020 and over
1 million in 2050.
Urbanization appears to be associated with an increased
prevalence of osteoporosis due to lifestyle habits such as
sedentary lifestyle, increased indoor living, and lower sun
exposure [4]. The awareness of osteoporosis is low in India,
with surveys indicating that only 10–15% of Indians are
aware of the disease [17]. According to the International
Osteoporosis Federation, the availability of dual-energy
X-ray absorptiometry instruments (DXA), a key tool for
diagnosing osteoporosis, is about 0.26 per million in India,
far below the recommended number of 10.6 per million [18].
Moreover, most of the DXA instruments are located in urban
areas, and even many large cities in India do not have DXA
facilities. Furthermore, the fact remains that the cost of DXA
and osteoporosis treatments are largely not covered by insurance. Indians fare poorly compared to the more developed
Asian countries like Japan and Korea, where availability of
DXA is much higher (20.8 and 24.5 per million, respectively) [19]. Besides, only 20% of patients with osteoporosis
are diagnosed and treated in India [20]. Even then, the treatment compliance rate is only around 64% [20].
Apart from the fact that osteoporosis is often asymptomatic (until the patient sustains a fracture), and its treatment
is usually life-long and costly, the lack of a definite local
consensus guideline makes management of osteoporosis in
India even more difficult. The Indian Menopause Society
published clinical practice guidelines on postmenopausal
osteoporosis in 2013 [21]; however, new guidelines need to
be formulated based on recent clinical evidence.
The Indian Society for Bone and Mineral Research
(ISBMR), which is a multidisciplinary group of physicians,
researchers, dietitians, and epidemiologists and who study
bone and related tissues, in their annual meeting, drafted the
guidelines for the diagnosis and management of osteoporosis
that would be appropriate in a resource constraint setting
like India. The position paper has been discussed under the
heads, as summarized in Table 1.
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Table 1  Summarizing the points that the expert committee have considered while drafting the consensus
Risk factors for osteoporosis
Diagnosis of osteoporosis
Indications for treatment
Pharmacological management of osteoporosis
Follow-up for patients with osteoporosis

Table 2  Summarizing the non-modifiable and modifiable risk factors
for primary osteoporosis
Non-modifiable risk factors

Modifiable risk factors

Age
Sex
Ethnicity
Genetics

Nutrition
Calcium intake
Vitamin D intake
Lifestyle factors—
smoking, alcohol,
exercise
Use of medications

Peak bone mineral density

Risk factors for osteoporosis
Various risk factors that contribute to postmenopausal osteoporosis are broadly classified as non-modifiable or modifiable risk factors and have been summarized in Table 2.
Non-modifiable risk factors include sex, age, ethnicity,
and genetics. Women have a smaller body frame size, and
in a developing country like India, are more likely to have
lower consumption of calcium-rich foods and inadequate
sunlight exposure because of cultural or secular reasons.
Furthermore, estrogen deficiency resulting from menopause contributes in a significant way to the development
of osteoporosis. Although the average age at menarche in
Indian girls is ~ 12.5 years, the average age at menopause
is 46.2 years which is earlier than that seen in non-Indian
women [22], and this is a significant risk factor for the development of osteoporosis in Indian women [13, 23]. Numerous
studies have reported increasing prevalence of osteoporosis
with advancing age, and this trend has been observed to a
great extent among Indian women compared to men [9, 13].
Genetic factors, race, and ethnicity also have a major
influence on peak bone mass attainment. Asian Indian
women have been shown to have 5–15% lower bone mineral density (BMD) than non-Asian women [24–26]. Also,
polymorphisms in the gene for vitamin D receptors in different races have been suggested to contribute to the ethnic
differences in BMD [4, 27, 28].
Modifiable risk factors include the following:
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1. Nutritional factors: Calcium and vitamin D, the two primary nutrients involved in bone health, play a major role
in influencing the risk of osteoporosis.
a. Calcium: Calcium in the form of hydroxyapatite crystals is deposited in the bone matrix and is
responsible for bone hardness. Calcium is obtained
from the diet through dairy as well as non-dairy
sources. The bioavailability of calcium from dairy
sources is much higher than non-dairy sources.
Several studies have reported that Indian diets do
not meet the recommended dietary allowances of
600 mg/day of calcium for adult women as recommended by the Indian Council of Medical Research
[29]. Indian diets are predominantly vegetarian,
and the contribution of dairy products to the overall
calcium intake is minimal in the lower socioeconomic classes. Furthermore, the unequal distribution of milk and milk products, with boys and men
being served larger portions, is another factor that
worsens the situation [5]. According to Harinarayan
et al., Indian diets have a higher ratio of phytates
to calcium, especially among rural Indians [30].
Phytates may hinder calcium absorption from the
already calcium-deficient diets. A survey conducted
in 2011–2012 in India reported a dietary calcium
intake of only 429 mg/day [31].
b. Vitamin D: Vitamin D is synthesized in the human
skin upon exposure to sunlight. Although there is
no dearth of sunlight in India, several reports have
shown that Indians suffer from vitamin D deficiency
[32–34]. Some of the reasons for vitamin D deficiency among Indians may be lower sun exposure
due to indoor lifestyle, traditional clothing leading to less skin exposure to sunlight (saris, salwarkameez, etc.), inadequate dietary intake, poor vitamin D fortification of foods, and darkly pigmented
skin and atmospheric pollution [18, 35]. Vitamin D
deficiency results in ineffective calcium absorption
from the gut, which in turn affects the mineralization
of bones. The findings of the Delhi Vertebral Osteoporosis Study (DeVOS) from India suggest that the
odds of having osteoporotic fractures in subjects
consuming calcium and vitamin D supplements are
lower [36].
2. Nutritional status: Poor nutritional status is also a major
contributing factor for osteoporosis, especially in India.
Bodyweight lower than 60 kg significantly increases the
risk of osteoporosis in women [23]. Several pathways
link body weight and bone, and both lean and fat masses
are determining factors for BMD. Various studies have
demonstrated a positive correlation between body mass
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index (BMI) and BMD [37, 38]. Sarcopenia has also
been shown to be associated with low BMD [39].
3. Other lifestyle factors: Urbanization has resulted in
a sedentary lifestyle, decreased exposure to sunlight
(sometimes from traditional clothing use), and low
physical activity, which are detrimental to bone health
[18]. Physical exercise, especially weight-bearing exercise, helps to improve and maintain muscle and bone
strength and also helps to improve body balance [21].
Lack of exercise is significantly associated with lower
BMD in Indian women [38].
	  While being a major risk factor for osteoporosis,
cigarette smoking is low among Indian women to be
a significant risk for osteoporosis [23]. Heavy drinkers
have approximately a 1.7-times greater risk for osteoporosis than light drinkers [40]. However, the DeVOS
study reported that neither cigarette smoking nor alcohol
consumption was common in Indian women and was not
significantly associated with prevalent fractures [36].
	  Recent data suggest that type 1 (T1D) and type 2 diabetes mellitus (T2D) are significant risk factors for fractures. Bone mineral density tends to be low in patients
with T1D, BMD may be normal in patients with T2D,
and yet, the fracture risk is increased, reflecting poor
bone quality in these patients. It is not known whether
better control of diabetes mitigates the increased fracture
risk.
4. Medication use: Long-term over-the-counter glucocorticoid use [41] and minimum use of hormone replacement
therapy (HRT) in the Indian scenario are a predominant
cause of osteoporosis. In addition, use of proton pump
inhibitors and anticonvulsants have also been associated
with low BMD and osteoporosis [42–44].

Diagnosis of osteoporosis
Clinical
Any adult with a fragility fracture should be suspected of
having underlying osteoporosis (primary vs. secondary). In
addition, historical height loss of more than 4 cm in postmenopausal women raises the possibility of asymptomatic
vertebral fractures [45]. Individuals with persistent back
pain may have underlying vertebral fractures as well.

Dual‑energy X‑ray absorptiometry
Dual-energy X-ray absorptiometry, or DXA, is the most
commonly used technique for measuring BMD. Although
true density measurement is 3-dimensional, DXA is a twodimensional measurement and thus calculates areal bone
density [46]. We recommend against the use of quantitative
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ultrasound (QUS) for screening or initial decision-making
regarding treatment of osteoporosis.
Bone mineral density values are calculated in grams per
cm2 (or area of bone density). In order to account for the differences across DXA equipment across different manufacturers, the values are further expressed in standard deviations (SD) units from the mean BMD value of the reference
population [47]:
• “T” score of an individual is the number of SD his/her

BMD deviates from the mean BMD of 20–29-year-old
reference population (usually Caucasian women—see
further discussion below).
• “Z” score of an individual is the number of SD his/her
BMD deviates from the mean BMD of the same age,
gender, and ethnic group reference population.
Whether the reference population should be matched for
sex and ethnicity is a matter of debate [48]. Most of the data
on fracture/BMD relationship has been derived using young
Caucasian women as the reference population. The 2019
International Society for Clinical Densitometry (ISCD) Official Position recommends the use of a uniform Caucasian
(non-race adjusted) female normative database for women
of all ethnic groups. It also states that manufacturers should
continue to use NHANES III data as the reference standard
for femoral neck and total hip T-scores [49].
Although normative data on BMD in healthy Indian
adults exist [9, 50, 51], at present, there is insufficient data
to assess the fracture risk using the Indian BMD reference
database. Hence, for all practical purposes and in line with
the 2019 ISCD Official Position, the Caucasian female database derived from the NHANES III is used as India’s reference population for calculating T-scores [52]. With regard to
males, the 2019 ISCD Official Position recommends the use
a uniform Caucasian (non-race adjusted) female reference
for men of all ethnic groups; nevertheless, most manufacturers continue to use the young male Caucasian database as
the reference population.
The purpose of measuring BMD with DXA is to identify
individuals at risk of developing future fractures so that preventative strategies can be employed. In addition, changes in
BMD measurements over time may be of value in determining response to therapy.

Indications for DXA measurement
The number of available DXA scanners is limited in India,
with only 0.26 scanners for 1 million population [18]. This
necessitates a judicious use of DXA facilities. Simultaneously, there is a dearth of adequate utilization of DXA
by specialties treating individuals at risk for osteoporosis
in India [53]. Accordingly, as a trade-off, the following
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indications from the National Osteoporosis Foundation
(NOF) can be adopted for DXA measurement recommendations [54]. Since data indicates that osteoporotic fractures occur at an earlier age in Indians than in the West, we
recommend screening at an earlier age [5, 55].
• Women aged 60 and older and men aged 65 and older,

regardless of clinical risk factors

• Postmenopausal women younger than 60 years and men
•

•
•

•

aged 50–64 years when there are concerns for osteoporosis based on their clinical risk factor profile
Women in the menopausal transition if there is a specific risk factor associated with increased fracture risk,
such as low body weight, prior low-trauma fracture, or
high-risk medication
Individuals who have had a fragility fracture before the
age of 50 years
Individuals with a condition (e.g., rheumatoid arthritis, diabetes mellitus, malabsorption syndrome) or who
are taking medication (e.g., glucocorticoids in a daily
dose ≥ 5 mg prednisone or equivalent for ≥ 3 months)
associated with low bone mass or bone loss
Any individual being considered for pharmacologic
therapy for osteoporosis

Biochemical investigations
Biochemical investigations should be directed at identifying the underlying cause of osteoporosis. In patients
with osteoporosis, prior to initiation of pharmacotherapy,
a basic biochemical and hormonal profile that includes
serum calcium, phosphorous, total alkaline phosphatase,
creatinine, 25-hydroxyvitamin D, and intact parathyroid
hormone (iPTH) would be desirable [56]. In patients with
secondary osteoporosis, detailed blood investigations
should be pursued based on clinical suspicion (Table 3).

Bone turnover markers
Bone turnover markers (BTMs) are dynamic parameters
that reflect short-term, acute changes in bone remodeling
status that are not measured by BMD and hence, are complementary to BMD measurement. However, BTMs have
no role in the diagnosis of osteoporosis. Although BTMs
are not routinely used to diagnose osteoporosis, they are
increasingly used in the follow-up of patients who are on
anti-osteoporotic treatments. Hence, wherever available,
patients contemplating anti-osteoporotic therapy can get a
baseline BTM level estimated prior to initiation of therapy
for subsequent comparison during follow-up [57].
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Table 3  Summarizing the biochemical investigations recommended by the expert committee to delineate the underlying cause of osteoporosis
Mandatory tests to be done in all patients with
osteoporosis

Specific tests to be done in suspected secondary osteoporosis

Complete blood count
Total calcium
Inorganic phosphate
Total alkaline phosphatase
Kidney function test

Erythrocyte sedimentation rate and serum electrophoresis for suspected multiple myeloma
IgA tissue-transglutaminase antibody (IgA tTg) in suspected celiac disease
Serum testosterone (in men) and estradiol (in women) in suspected hypogonadism
Overnight dexamethasone suppression test in suspected Cushing’s syndrome
Fasting blood glucose, post-prandial blood glucose and glycated hemoglobin in a known
or suspected case of diabetes mellitus

Liver function test
25-hydroxyvitamin D
Intact parathyroid hormone
TSH

Indications for treatment
The decision to initiate anti-osteoporotic treatment should be
based on clinical screening tools such as fracture risk assessment tool (FRAX) and imaging, including DXA scan or
plain radiography. FRAX is an online tool that assesses the
10-year fracture risk of major osteoporotic fractures (wrist,
vertebral, hip, and shoulder) based on various risk factors.
FRAX thresholds for initiating anti-osteoporotic treatment
vary among different ethnicities [58]. The Endocrine Society guidelines broadly recommend treating postmenopausal women at high risk of fractures, especially those with a
recent fragility fracture [59]. Nevertheless, the ultimate goal
of initiating treatment for management of osteoporosis is to
reduce the burden of fragility fractures due to morbidity,
mortality, and associated costs. The key indications for initiating therapy for osteoporosis are summarized in Table 4.

Clinical indications for initiating therapy
A clear clinical indication for starting treatment in postmenopausal women presenting with a major osteoporotic
fracture (hip, spine, wrist, or humerus) that was found clinically or on imaging. The presence of fracture is a better
predictor of future fracture risk than T-score obtained by
DXA scan in such patients [60, 61]. There is strong evidence

to suggest that individuals presenting with hip or spine fractures if treated appropriately for osteoporosis have significant reductions in future risk of a recurrent fracture.
Based on previously published literature, it is evident
that a recent fracture (within the past 2 years) is a good
predictor of imminent fracture risk in the near future [62,
63]. This holds true for recent vertebral fractures [64] and
non-vertebral fragility fractures such as wrist and humerus
fractures [65]. Pharmacological therapies should be started
in patients with recent fractures to prevent subsequent fractures, but data on the optimal timing of initiation of therapy
after a fracture are sparse. Based on the Horizon trial [61],
it is recommended to begin treatment at least 2 weeks after
a hip fracture.

Indications of therapy based on bone mineral
density
Based on BMD, anti-osteoporotic treatment is indicated in individuals over 50 years of age and with DXA
T-score ≤ –2.5 at femoral neck, total hip, and lumbar spine.
There is evidence that fracture risk is significantly reduced in
these individuals following anti-resorptive or anabolic antiosteoporotic therapy [66, 67]. Treatment of osteoporosis
should be considered if lumbar spine, total hip, or femoral
neck BMD T-scores are ≤  − 2.5.

Table 4  Summarizing the key indications for initiating anti-osteoporotic therapy
• A vertebral fracture (clinically apparent or found on vertebral imaging) or non-vertebral fracture (hip, wrist, and humerus)
• In individuals > 50 years of age with T-score ≤  − 2.5 at femoral neck or total hip or lumbar spine measured by DXA
• In individuals with osteopenia (T-score between − 1.0 and − 2.5 at the femoral neck or lumbar spine) with clinical risk factors or a 10-year
probability of a hip fracture ≥ 3.5% or a 10-year probability of a major osteoporosis-related fracture ≥ 10.5% based on the FRAX tool (based on
limited data in Indians)
• In individuals with type 2 diabetes mellitus, the intervention threshold should be increased to T-score ≤  − 2.0 at femoral neck or total hip or
lumbar spine measured by DXA [76]
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Among individuals with BMD below the expected range
for age (BERA) and low bone mass (T-score between − 1.0
and − 2.5 at the femoral neck or lumbar spine), it is advisable to initiate treatment based on clinical risk factors or
on an increased FRAX score. A FRAX score predicting
the 10-year probability of a hip fracture ≥ 3%, or a 10-year
probability of a major osteoporosis-related fracture ≥ 20%,
is indicative of an increased risk of fracture in the future.
Derivation of Indian-specific FRAX is based on the fracture risk in individuals living in Singapore and, therefore,
may not be fully applicable in the native Indian population.
Using the NOF treatment cut-off guidelines of 3% risk for
hip fracture and 20% risk for MOF, Indian-specific FRAX
may underestimate the fracture risk [68]. Based on studies
of Indian patients with hip fractures, these thresholds may
be lower, and studies are underway to define these lower
treatment thresholds [58, 69]. However, more evidence is
needed to support whether treatment initiation based on
these criteria truly results in absolute fracture risk reduction. Till conclusive data is available, it is prudent to use
white Caucasian database in clinical practice.
Trabecular bone score (TBS), a tool that assesses bone’s
microarchitecture, has emerged as a valuable modality complementary to BMD [70, 71]. Recently, TBS has
revealed significant improvements in bone structure following administration of yearly zoledronic acid in a cohort
of Indian patients. A pan-India reference for TBS is underway [72]; however, therapeutic guidelines and thresholds
cannot currently be based on TBS [73].

Pharmacological management
of osteoporosis

Role of other screening tools

• Teriparatide is an effective anabolic agent to initi-

Several other osteoporosis screening tools have been
validated in both women and men in the Indian population. These tools are based on simple clinical risk factors
and could be easily used in community settings [74]. In a
large cohort of rural postmenopausal women, the SCORE
(Simple Calculated Osteoporosis Risk Estimation) screening tool was useful, with good sensitivity and good area
under the curve for predicting femoral neck osteoporosis
on BMD measurement. It uses simple clinical risk factors
like age, weight, previous fracture, estrogen therapy, rheumatoid arthritis, and ethnicity. A value ≥ 6 was found to
have good sensitivity and specificity for estimating risk in
the Indian population [75]. Similarly, the risk assessment
tools OSTA (osteoporosis self-assessment tool for Asians)
and MORES (male osteoporosis risk estimation score)
have been validated for use in the Indian population [76].
These tools are rapid, easy to perform, inexpensive, and
easily usable in the rural Indian setting, but the impact of
initiating therapy based on thresholds derived from these
tools is not well studied.
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Fundamentals of osteoporosis management [77]
• Maintain serum 25-hydroxyvitamin D (25[OH]
•

•
•

•
•
•
•

D) ≥ 20 ng/mL in all patients with osteoporosis. However, we feel that a level of 30–40 ng/mL would be ideal.
Supplement with vitamin D3 if needed; 1000 to 2000
international units (IU) of daily maintenance therapy
is typically required to maintain an optimal serum
25(OH)D level in Indians.
Higher doses of vitamin D may be necessary in the
presence of certain factors (e.g., obesity, malabsorption, older individuals)
Counsel patients to maintain adequate dietary intake
of calcium with a total intake (including diet plus
supplement, if needed) of at least 1000 mg/day for
women ≥ 50 years [3]
Counsel patients to limit alcohol intake to no more than
2 units per day
Counsel patients to stop smoking
Counsel patients to maintain an active lifestyle, including weight-bearing and balance exercises
Provide counseling on reducing the risk of falls, particularly among older patients

Recommendations for initial first‑line therapy
for individuals with prevalent vertebral fractures
ate therapy in these cases, which to be continued for
24 months and followed by antiresorptives.
• Intravenous zoledronic acid or denosumab are also
effective options. Since the protocol for discontinuing
denosumab is still not firmly established, zoledronic
acid is usually preferred as initial therapy for 3–5 years.
• Oral bisphosphonates can be used if the patient wants
to avoid injectable therapies.

Recommendations for initial first‑line therapy
for individuals with prevalent hip fracture
• Intravenous zoledronic acid is the agent of choice in

this group—it is recommended that hospitalized/postsurgical patients with hip fracture be given a dose of
intravenous zoledronic acid before being discharged
from the hospital.
• Denosumab is also an apt and effective choice but is often
used after zoledronic acid, for reasons explained above.
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• While teriparatide can be used in this situation, there is

limited data available in the prevention of hip fracture
[78].

Recommendations for initial first‑line therapy
for high‑risk individuals without prevalent fractures
• Bisphosphonates are generally agents of choice for those

at high risk for fracture. While either weekly oral (alendronate, risedronate) or annual intravenous agents are
effective, concerns about compliance and ease of once
a year administration has made zoledronic acid the preferred drug for most patients. Both options should be
discussed with the patient (weekly oral vs. annual intravenous) and treatment chosen accordingly. Denosumab
can be used as a first choice too if the patient reacts to or
wants to avoid bisphosphonates. Teriparatide can be considered for some with very low BMD (T score <  − 3.5)
and high risk of vertebral fracture.
• The risk of rebound fractures is increased if subsequent
doses of denosumab are not administered in time.

Recommendations for initial first‑line therapies
for low and moderate risk cases for vertebral,
non‑vertebral, and hip fractures
• Approved agents with efficacy to reduce hip, non-verte-

bral, and spine fractures include alendronate, risedronate,
zoledronic acid, and denosumab, and these are appropriate as initial therapy for most patients at risk of fracture.
Often, oral bisphosphonates are preferred in low and
moderate risk cases.

Recommendations for the management
of osteoporosis in chronic kidney disease patients
and those on haemodialysis
• Management of patients with osteoporosis and chronic

kidney disease (CKD) is difficult as bisphosphonates are
contraindicated in stage 4 and 5 kidney disease (eGFR
below 30 to 35 mL/min). Denosumab is not cleared by
the kidney and therefore can be used in these patients.
However, the risk of hypocalcemia is high with this
agent, especially in patients in stage 5 disease. Optimal
calcium intake and vitamin D status should be assured
before starting denosumab.
• A major concern with antiresorptive therapy in patients
with CKD is dynamic bone disease and selected patients
should undergo undecalcified iliac bone biopsy if facilities are available, to guide correct decision-making for
the management of osteoporosis.
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Recommendations for the use of Hormone
Replacement Therapy (HRT) in the management
of osteoporosis [79]
• Although effective in increasing bone mass and prevent

fractures, HRT is not recommended for managing osteoporosis due to high risk of side effects such cardiac events and
breast cancer (although breast cancer risk is not increased
with estrogens alone). Hormone Replacment Therapy can
be used when there is an additional indication to use estrogens such as uncontrollable menopausal symptoms. In
select cases (within the first 10 years after menopause in
women without contraindications), HRT can be used for
prevention of postmenopausal osteoporosis.
• Testosterone therapy may be added in androgen-deficient
men (testosterone level less than 200 ng/dL on more than
one determination) if accompanied by signs or symptoms of androgen deficiency (e.g., low libido, unexplained chronic fatigue, loss of body hair, hot flushes) or
“organic” hypogonadism (due to hypothalamic, pituitary,
or specific testicular disorder). If testosterone treatment
does not alleviate symptoms of androgen deficiency after
3–6 months, it should be discontinued, and other therapies considered. It should be noted that anti-resorptive
and anabolic drug therapies are equally effective for
osteoporosis in men as well.

Recommendations for the use of intranasal
calcitonin in the management of osteoporosis [59]?
• Intranasal calcitonin can be used for temporary bone pain

relief.

• However, calcitonin’s effectiveness in prevention of

osteoporotic fractures is very limited and should therefore be prescribed only in women who cannot tolerate
bisphosphonates, denosumab, teriparatide, or raloxifene
or for whom these therapies are not considered appropriate.

Recommendations for the use of combination
therapies in the management of osteoporosis [79]
• Combination therapy can be considered in patients with

very high or imminent fracture risk [80]. The use of
teriparatide and denosumab has been shown to result in
a great increase in BMD as against either agent alone.
However, fracture prevention data are not yet available.

Recommendations for the use of sequential
therapies in the management of osteoporosis [79]
• Treatment with teriparatide should always be followed

by antiresorptive agents to prevent bone density decline
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and loss of fracture efficacy. Either bisphosphonates or
denosumab can be used in this setting.
• In patients unresponsive to anti-resorptive therapy alone,
treatment can be followed by a combination of teriparatide and anti-resporptives [81].
• Treatment with denosumab, if it has to be discontinued,
should be followed by bisphosphonate, either zoledronate
[82] or alendronate [83] in patients with adequate renal
function. Delay in denosumab therapy or lack of an alternate therapy 6 months after last denosumab dose is associated with a rebound increase in fractures.
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of treatment and regular follow-ups should be reinforced
and family members/caregivers should be actively involved
in decision-making.

Physical evaluation
A short physical examination focusing on the patient’s
height should be undertaken. Other characteristics to assess
include spinal tenderness, kyphosis, decreased spacing
between lower ribs and pelvis, and oral hygiene. Patients on
anti-resorptive therapy with poor dentition may be referred
to a dental physician for a detailed oral evaluation.

Follow‑up for patients with osteoporosis

Biochemical evaluation

Treatment of osteoporosis with either anti-resorptive or
osteoanabolic therapy reduces the risk of incident fractures
along with a subsequent reduction in morbidity and mortality. In a study assessing treatment algorithms in patients
with osteoporosis in India, most clinicians preferred bisphosphonates as the first line of therapy [84]. However, in
another study that aimed explicitly to evaluate the treatment
adherence and compliance of postmenopausal osteoporotic
women for different regimens of bisphosphonates in Indian
postmenopausal women, the authors found that an adherence
rate of 56% was found with the monthly regimens, 36% for
weekly regimens, and 32% for daily regimens [85]. Herein
lies the paramount importance of continuous monitoring and
vigilant follow-up.

Although no consensus exists, we recommend estimating
serum 25-hydroxyvitamin D at 6-month intervals for the
initial 2–3 visits, and thereafter annually, to ensure vitamin D sufficiency while on treatment and target a serum
25-hydroxyvitamin D of at least 20 ng/ml.
Therapy with teriparatide is occasionally associated with
hypercalcemia [67]. Serum calcium can be measured at least
12 h after administering the first injection of teriparatide
because serum calcium levels can be transiently elevated
within 6 h of injection. If a patient develops hypercalcemia,
oral calcium intake should be reduced by 50% and serum
calcium repeated. If a patient develops persistent hypercalcemia, calcium supplementation should be stopped, although
discontinuation of teriparatide is rarely needed. An assessment for other causes of hypercalcemia (e.g., hyperparathyroidism, malignancy, sarcoidosis, or hydrochlorothiazide)
should be undertaken simultaneously [86, 87].

Frequency of follow‑up
There exists no consensus regarding the frequency of follow-up for patients on anti-osteoporotic therapy. The first
follow-up can be planned after 3 months following initiation of therapy. Thereafter, patients can be followed up at
3–6 monthly intervals for 2–3 subsequent contacts followed
by annual visits [21]. This promotes adequate adherence to
the treatment regime and reinforcement of fall prevention
practices.

Clinical follow‑up
History
At each visit, a brief history with an emphasis on assessing
new incident fractures, new-onset/worsening of kyphosis/
scoliosis, new-onset or worsening of back pain, and perceptible height loss should be elicited. A history of falls is
a predictor of future falls and hence should be specifically
queried. Patients should also be asked about the possible
side effects of anti-osteoporotic therapy, notably, thigh and
jaw pain. At each and every visit, the need for continuation
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Radiology
A new radiograph of the spine may be ordered at annual
follow-up for all patients, particularly for patients complaining of new-onset or worsening back-pain/kyphosis to rule
out any incident vertebral fractures. In addition, patients on
bisphosphonate therapy complaining of thigh pain should
undergo a radiograph of the upper femur to rule out cortical beaking, the precursor of atypical femoral fracture [88].
Similarly, patients on anti-resorptive therapy with suspected
osteonecrosis of the jaw should undergo a computed tomography of the jaw to rule out the same.

Bone mineral density
Treatments for osteoporosis increase BMD, but only modestly. Evidence to support the use of BMD to monitor the
treatment response is weak, but suggests that BMD can be
used for this purpose [89]. The latest Endocrine Society
guidelines suggest monitoring of BMD by DXA at the spine
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and hip every 1–3 years to assess treatment response [59].
In the Indian scenario, repeating DXA every 1–2 years is
recommended. It has been suggested that serial BMD measurements in treated patients may identify individuals who do
not adhere to treatment or have a secondary cause for bone
loss. An increase in BMD above the least significant change
(LSC) with treatment is good and is associated with a greater
reduction in fracture risk than a stable BMD [90]. Usually,
changes in lumbar spine BMD are more robust, while those
at the hip are less dramatic, irrespective of the treatment
modality used [91]. A stable BMD on treatment is also an
acceptable endpoint; however, a loss of BMD beyond the
LSC (usually 5% in the lumbar spine, 4% in the total hip,
and 5% in the femoral neck) over 2 years suggests treatment
failure. In addition, having two or more fractures, especially
vertebral fractures, while on therapy also constitutes treatment failure [92]. In such a case, low compliance, improper
dosing, vitamin D deficiency, celiac disease, multiple myeloma, concurrent glucocorticoid use, and endocrinopathies
(e.g., primary hyperparathyroidism, Cushing’s syndrome,
thyrotoxicosis, and unrecognized hypophosphatemic states)
should all be considered [59, 93, 94].
Assessing changes in BMD on serial follow-up measurements requires careful attention to detail. Using the same
scanner and a well-trained technologist who is aware of the
pitfalls of bone densitometry can mitigate these problems.
The provider responsible for reporting the results also needs
to be aware of assay limitations. Degenerative changes in the
spine or a new fracture in the region of interest may falsely
give the impression of BMD gain.

Bone turnover markers
Bone turnover markers (BTMs) reflect the underlying bone
turnover status. BTMs are dynamic parameters that can
reflect short-term/acute changes in bone that are often
missed by BMD. Hence, BTMs reflect the therapeutic
responses to anti-osteoporosis therapies much earlier than
BMD, and therefore can be used in clinical practice, especially to monitor compliance and adherence to treatment
[57]. The absolute values or the degree of change from
baseline for BTMs can be used; considering the ethnic variations in BTMs and the pre-analytical variables involved
in their measurement, using the degree of change rather
than absolute values is more reasonable. Of the commercially available BTM clinical tests, the International Osteoporosis Foundation (IOF) and the International Federation
of Clinical Chemistry and Laboratory Medicine (IFCC)
recommend using serum type I collagen C-telopeptide
(CTx) and serum procollagen type I N-propeptide (PINP).
A consensus statement on the use of BTMs for short-term
monitoring of osteoporosis treatment in the Asia–Pacific
region has recently been published, and in the absence
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of robust data from India, an analogy can be drawn from
the aforementioned guideline [95]. CTx and/or PINP can
be used to evaluate patient adherence and drug responses
to anti-resorptive agents, with measurements suggested
at baseline, 3, 6, and 12 months after starting treatment.
Similarly, PINP can be used to evaluate patient adherence
and drug responses to anabolic agents, with measurements
at baseline, 1 to 3 months, 6 months, and 12 months after
starting anabolic treatment. A decrease in CTx by at least
30% or by at least 100 ng/L from the pre-treatment value
is expected in a patient on anti-resorptive therapy [92, 96].
For PINP, a threshold of > 20% or > 10 μg/L from baseline
is considered to be significant [92, 97, 98]. The above cutoffs, however, do not apply for combination and sequential
therapies with anti-osteoporotic medications.

Drug holiday
The concept of a “drug holiday” has been proposed to
potentially reduce the incidence of the rare adverse events
associated with long-term anti-resorptive therapy [99].
However, the recommendation for drug holidays is still a
matter of debate [100], especially since there is a dearth
of data from India. However, the Endocrine Society
guidelines 2020 do recommend a drug holiday in selected
groups of patients [59]. In patients on bisphosphonate
therapy, fracture risk needs to be evaluated after 3–5 years
(3 years for intravenous, 5 years for oral therapy). Patients
with high-risk (defined as prior spine or hip fracture, or
a BMD T-score at the hip or spine of − 2.5 or below, or
10-year hip fracture risk ≥ 3%, or risk of major osteoporotic fracture risk ≥ 20%) or very high risk of fracture
(defined as multiple spine fractures and a BMD T-score at
the hip or spine of − 2.5 or below) are not deemed eligible
for drug holiday.
On the contrary, patients qualifying as having low risk
(defined as no prior hip or spine fractures, a BMD T-score
at the hip and spine both above − 1.0, and 10-year hip fracture risk < 3% and 10-year risk of major osteoporotic fractures < 20%) or moderate risk (defined as no prior hip or
spine fractures, a BMD T-score at the hip and spine both
above − 2.5, or 10-year hip fracture risk < 3% or risk of
major osteoporotic fractures < 20%) of fracture can be considered for drug holiday; however, fracture risk needs to be
evaluated regularly at 2–4 year intervals, with therapy being
reinstituted if the patient falls into the high-risk category.
In patients on denosumab therapy, fracture risk needs to be
evaluated in 5–10 years. A drug holiday can be considered
in low-moderate risk patients following a course of bisphosphonate with fracture risk being revaluated every 1–3 year.
There is no consensus on using BTMs to assess the need for
drug holiday [95].
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Osteoporosis education—fall prevention
Fall prevention is an integral part of comprehensive osteoporosis care, and physicians following up patients with
osteoporosis should educate patients about fall prevention.
Important points that need to be reiterated at each visit
include use of low-heeled shoes with rubber soles for more
solid footing, avoiding walking on slippery floors/sidewalks, using hand rails while walking up or downstairs,
keeping rooms, bathrooms, and stairs well lit, securing
in-room carpets, and installing grab bars on the bathrooms
walls.

Conclusions
Osteoporosis is a major public problem in India. However, diagnosing and effectively managing osteoporosis is
challenging in the Indian setting. Since data indicates that
osteoporotic fractures occur at an earlier age in Indians
than in the West, screening for osteoporosis should begin
at an earlier age. Maintaining optimum serum 25-hydroxyvitamin D levels is essential, which, in most cases, would
require regular vitamin D supplementation. Pharmacotherapy should be guided by the presence/absence of vertebral/
hip fractures or the severity of risk based on clinical factors, although bisphosphonates remain the first choice in
most cases. Regular follow-up is essential to ensure adherence and response to therapy.
Author contribution All authors contributed to the study conception
and design. The initial version of the manuscript was drafted by Sanjay
K. Bhadada, Manoj Chadha, Usha Sriram, Rimesh Pal, Thomas Paul,
Nitin Kapoor, Ameya Joshi, Beena Bansal, Sushil Gupta, and Ambrish
Mithal. The initial draft was edited and revised by Sanjay K. Bhadada,
Ambrish Mithal, Satinath Mukhopadhay, Soham Mukherjee, Mahendra
K. Garg, Narendra Kotwal, Nikhil Tandon, Rajesh Khadgawat, Subhash
C. Kukreja, and Sudhaker D. Rao. All authors read and approved the
final version of the manuscript.

Compliance with ethical standards
Ethics approval Being a position statement, ethical committee approval
was not required.
Consent to participate Not applicable.
Conflicts of interest None.

13

Archives of Osteoporosis

(2021) 16:102

References
1. Kanis JA, Johnell O, Oden A et al (2000) Long-term risk of
osteoporotic fracture in Malmö. Osteoporos Int 11:669–674.
https://doi.org/10.1007/s001980070064
2. Melton LJ, Atkinson EJ, O’Connor MK et al (1998) Bone density and fracture risk in men. J Bone Miner Res 13:1915–1923.
https://doi.org/10.1359/jbmr.1998.13.12.1915
3. Roux C, Briot K (2020) The crisis of inadequate treatment in
osteoporosis. Lancet Rheumatol 2:e110–e119. https://doi.org/
10.1016/S2665-9913(19)30136-5
4. Malhotra N, Mithal A (2008) Osteoporosis in Indians. Indian
J Med Res 127:263–268
5. Khadilkar A, Mandlik R (2015) Epidemiology and treatment
of osteoporosis in women: an Indian perspective. Int J Womens
Health 841. https://doi.org/10.2147/IJWH.S54623
6. Agrawal T, Verma AK Cross sectional study of osteoporosis
among women. Med J Armed Forces India 69:168–171. https://
doi.org/10.1016/j.mjafi.2012.07.024
7. Babu A, Ikbal F, Noone M et al (2009) Osteoporosis and osteopenia in India: a few more observations. Indian J Med Sci
63:76. https://doi.org/10.4103/0019-5359.49242
8. Kadam N, Chiplonkar S, Khadilkar A et al (2010) Low bone
mass in urban Indian women above 40 years of age: prevalence
and risk factors. Gynecol Endocrinol 26:909–917. https://doi.
org/10.3109/09513590.2010.487604
9. Marwaha RK, Tandon N, Garg MK et al (2011) Bone health in
healthy Indian population aged 50 years and above. Osteoporos
Int 22:2829–2836. https://doi.org/10.1007/s00198-010-1507-8
10. Sharma S, Tandon V, Mahajan A et al (2006) Preliminary
screening of osteoporosis and osteopenia in urban women from
Jammu using calcaneal QUS. Indian J Med Sci 60:183. https://
doi.org/10.4103/0019-5359.25679
11. Gandhi AB, Shukla AK (2005) Evaluation of BMD of women
above 40 years of age. J Obstet Gynecol India 55:265–267
12. Vaidya SV, Ekbote VH, Khadilkar AV et al (2012) Bone status
of women over 40 years of age from two socioeconomic strata.
Endocr Res 37:25–34. https://doi.org/10.3109/07435800.2011.
601384
13. Unni J, Garg R, Pawar R (2010) Bone mineral density in
women above 40 years. J Midlife Health 1:19. https://doi.org/
10.4103/0976-7800.66989
14. Shatrugna V, Kulkarni B, Kumar PA et al (2005) Bone status
of Indian women from a low-income group and its relationship
to the nutritional status. Osteoporos Int 16:1827–1835. https://
doi.org/10.1007/s00198-005-1933-1
15. Agrawal NK, Sharma B (2013) Prevalence of osteoporosis in
otherwise healthy Indian males aged 50 years and above. Arch
Osteoporos 8. https://doi.org/10.1007/s11657-012-0116-x
16. Shetty S, Kapoor N, Naik D et al (2014) Osteoporosis in
healthy south Indian males and the influence of life style factors and vitamin D status on bone mineral density. J Osteoporos 2014:1–5. https://doi.org/10.1155/2014/723238
17. Nallasivan S (2019) Current treatment of osteoporosis. Indian
J Rheumatol 14:57. https://doi.org/10.4103/injr.injr_74_18
18. Mithal A, Bansal B, Kyer C, Ebeling P (2014) The Asia-Pacific
regional audit-epidemiology, costs, and burden of osteoporosis
in india 2013: a report of international osteoporosis foundation.
Indian J Endocrinol Metab 18:449. https://doi.org/10.4103/
2230-8210.137485
19. Joshi A, Bhagwat N, Chadha M, Varthakavi P (2014) Osteoporosis treatment in India: call for action. Indian J Endocrinol
Metab 18:441. https://doi.org/10.4103/2230-8210.137482

Archives of Osteoporosis

Page 11 of 13

(2021) 16:102

20. Jhaveri S (2015) Current Clinical practice scenario of osteoporosis management in India. J Clin Diagn Res. https://doi.org/10.
7860/JCDR/2015/13000.6635
21. Singh M, Harinarayan CV, Marwah R et al (2013) Clinical practice guidelines on postmenopausal osteoporosis: an executive
summary and recommendations. J Midlife Health 4:107–126.
https://doi.org/10.4103/0976-7800.115293
22. Ahuja M (2016) Age of menopause and determinants of menopause age: a PAN India survey by IMS. J Midlife Health 7:126.
https://doi.org/10.4103/0976-7800.191012
23. Keramat A, Patwardhan B, Larijani B, et al (2008) The assessment of osteoporosis risk factors in Iranian women compared
with Indian women. BMC Musculoskelet Disord 9. https://doi.
org/10.1186/1471-2474-9-28
24. Alekel DL, Mortillaro E, Hussain EA et al (1999) Lifestyle and
biologic contributors to proximal femur bone mineral density and
hip axis length in two distinct ethnic groups of premenopausal
women. Osteoporos Int 9:327–338. https://d oi.o rg/1 0.1 007/s 0019
80050155
25. Alekel DL, Peterson CT, Werner RK et al (2002) Frame size,
ethnicity, lifestyle, and biologic contributors to areal and volumetric lumbar spine bone mineral density in Indian/Pakistani and
American Caucasian premenopausal women. J Clin Densitom
5:175–186. https://doi.org/10.1385/JCD:5:2:175
26. Vaidya R, Shah R (2010) Bone mineral density and reference
standards for Indian women. J Midlife Health 1:55. https://doi.
org/10.4103/0976-7800.76211
27. Ahmad I, Jafar T, Mahdi F et al (2018) Association of vitamin D
receptor gene polymorphism (TaqI and Apa1) with bone mineral
density in North Indian postmenopausal women. Gene 659:123–
127. https://doi.org/10.1016/j.gene.2018.03.052
28. Mitra S, Desai M, IkramKhatkhatay M (2006) Vitamin D receptor gene polymorphisms and bone mineral density in postmenopausal Indian women. Maturitas 55:27–35. https://doi.org/10.
1016/j.maturitas.2006.01.003
29. Nutrient requirements and recommended dietary allowances for
Indians: A Report of the Expert Group of the Indian Council of
Medical Research; 2009. Hyderabad: National Institute of Nutrition; Indian Council of Medical Research
30. Harinarayan CV, Ramalakshmi T, Prasad UV et al (2007) High
prevalence of low dietary calcium, high phytate consumption,
and vitamin D deficiency in healthy south Indians. Am J Clin
Nutr 85:1062–1067. https://doi.org/10.1093/ajcn/85.4.1062
31. Balk EM, Adam GP, Langberg VN et al (2017) Global dietary
calcium intake among adults: a systematic review. Osteoporos
Int 28:3315–3324. https://doi.org/10.1007/s00198-017-4230-x
32. Aparna P, Muthathal S, Nongkynrih B, Gupta S (2018) Vitamin
D deficiency in India. J Fam Med Prim Care 7:324. https://doi.
org/10.4103/jfmpc.jfmpc_78_18
33. Khadilkar A, Das G, Sayyad M et al (2007) Low calcium intake
and hypovitaminosis D in adolescent girls. Arch Dis Child
92:1045–1045. https://doi.org/10.1136/adc.2007.116376
34. G R, Gupta A, (2014) Vitamin D deficiency in India: prevalence,
causalities and interventions. Nutrients 6:729–775. https://doi.
org/10.3390/nu6020729
35. Agarwal KS, Mughal MZ, Upadhyay P et al (2002) The impact of
atmospheric pollution on vitamin D status of infants and toddlers
in Delhi, India. Arch Dis Child 87:111–113. https://doi.org/10.
1136/adc.87.2.111
36. Marwaha RK, Tandon N, Gupta Y et al (2012) The prevalence
of and risk factors for radiographic vertebral fractures in older
Indian women and men: Delhi Vertebral Osteoporosis Study
(DeVOS). Arch Osteoporos 7:201–207. https://doi.org/10.1007/
s11657-012-0098-8
37. Kumar A, Mittal S, Orito S et al (2010) Impact of dietary intake,
education, and physical activity on bone mineral density among

38.

39.

40.

41.

42.
43.

44.

45.

46.
47.
48.

49.

50.

51.
52.
53.
54.

102

North Indian women. J Bone Miner Metab 28:192–201. https://
doi.org/10.1007/s00774-009-0118-y
Raveendran A, Sen R, Dhaliwal L et al (2011) Prevalence and
related risk factors of osteoporosis in peri- and postmenopausal
Indian women. J Midlife Health 2:81. https://doi.org/10.4103/
0976-7800.92537
Pal R, Aggarwal A, Singh T et al (2020) Diagnostic cut-offs,
prevalence, and biochemical predictors of sarcopenia in healthy
Indian adults: the Sarcopenia-Chandigarh Urban Bone Epidemiological Study (Sarco-CUBES). Eur Geriatr Med. https://doi.
org/10.1007/s41999-020-00332-z
Jang H-D, Hong J-Y, Han K et al (2017) Relationship between
bone mineral density and alcohol intake: a nationwide health
survey analysis of postmenopausal women. PLoS ONE
12:e0180132. https://doi.org/10.1371/journal.pone.0180132
van Staa TP, van Staa TP, van Staa TP et al (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.
Osteoporos Int 13:777–787. https://d oi.o rg/1 0.1 007/s 00198 0200
108
Vinayan K, Nisha B (2006) Epilepsy, antiepileptic drugs and
bone health. Ann Indian Acad Neurol 9:90. https://d oi.org/10.
4103/0972-2327.25980
Paul T, Koshy G, Varghese R et al (2014) Derangements in bone
mineral parameters and bone mineral density in south Indian
subjects on antiepileptic medications. Ann Indian Acad Neurol
17:272. https://doi.org/10.4103/0972-2327.138489
Wang L, Li M, Cao Y, et al (2017) Proton pump inhibitors and
the risk for fracture at specific sites: data mining of the FDA
adverse event reporting system. Sci Rep 7. https://doi.org/10.
1038/s41598-017-05552-1
Siminoski K, Warshawski RS, Jen H, Lee K (2006) The accuracy
of historical height loss for the detection of vertebral fractures in
postmenopausal women. Osteoporos Int 17:290–296. https://d oi.
org/10.1007/s00198-005-2017-y
Rosenthal DI (1974) Tosteson AN (1989) Bone mass measurement, fracture risk, and screening for osteoporosis. Public Health
Rep Wash DC 104(Suppl):31–33
Cummings SR, Bates D, Black DM (2002) Clinical use of bone
densitometry: scientific review. JAMA 288:1889. https://d oi.o rg/
10.1001/jama.288.15.1889
Binkley NC, Schmeer P, Wasnich RD, Lenchik L (2002) What
are the criteria by which a densitometric diagnosis of osteoporosis can be made in males and non-caucasians? J Clin Densitom
5:s19–s27. https://doi.org/10.1385/JCD:5:3S:S19
Shuhart CR, Yeap SS, Anderson PA et al (2019) Executive summary of the 2019 ISCD position development conference on
monitoring treatment, DXA cross-calibration and least significant
change, spinal cord injury, peri-prosthetic and orthopedic bone
health, transgender medicine, and pediatrics. J Clin Densitom
22:453–471. https://doi.org/10.1016/j.jocd.2019.07.001
Aggarwal A, Pal R, Bhadada SK et al (2021) Bone mineral density in healthy adult Indian population: the Chandigarh Urban
Bone Epidemiological Study (CUBES). Arch Osteoporos 16:17.
https://doi.org/10.1007/s11657-020-00868-4
Makker A, Mishra G, Singh BP et al (2008) Normative bone mineral density data at multiple skeletal sites in Indian subjects. Arch
Osteoporos 3:25–37. https://d oi.o rg/1 0.1 007/s 11657-0 08-0 019-z
Kanis JA, McCloskey EV, Johansson H et al (2008) A reference
standard for the description of osteoporosis. Bone 42:467–475.
https://doi.org/10.1016/j.bone.2007.11.001
Binu AJ, Cherian KE, Kapoor N, et al (2018) Referral pattern
for DXA scanning in a tertiary care centre from southern India.
Arch Osteoporos 13. https://d oi.o rg/1 0.1 007/s 11657-0 18-0 548-z
Watts NB, Lewiecki EM, Miller PD, Baim S (2008) National
Osteoporosis Foundation 2008 Clinician’s Guide to Prevention and Treatment of Osteoporosis and the World Health

13

102

55.
56.

57.

58.

59.

60.

61.

62.
63.
64.

65.

66.
67.

68.

69.

70.

71.

Page 12 of 13
Organization Fracture Risk Assessment Tool (FRAX): what they
mean to the bone densitometrist and bone technologist. J Clin
Densitom 11:473–477. https://doi.org/10.1016/j.jocd.2008.04.
003
Gupta A (1996) Osteoporosis in India–the nutritional hypothesis.
Natl Med J India 9:268–274
Tannenbaum C, Clark J, Schwartzman K et al (2002) Yield of
laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab
87:4431–4437. https://doi.org/10.1210/jc.2002-020275
Shetty S, Kapoor N, Bondu J et al (2016) Bone turnover markers: emerging tool in the management of osteoporosis. Indian J
Endocrinol Metab 20:846. https://doi.org/10.4103/2230-8210.
192914
Bansal B, Mithal A, Chopra SR, et al (2018) Judicious use of
DXA-BMD in assessing fracture risk by using clinical risk factors in the Indian population. Arch Osteoporos 13. https://doi.
org/10.1007/s11657-018-0536-3
Eastell R, Rosen CJ, Black DM et al (2019) Pharmacological
management of osteoporosis in postmenopausal women: an
endocrine society* clinical practice guideline. J Clin Endocrinol
Metab 104:1595–1622. https://doi.org/10.1210/jc.2019-00221
Black DM, Cummings SR, Karpf DB et al (1996) Randomised
trial of effect of alendronate on risk of fracture in women with
existing vertebral fractures. The Lancet 348:1535–1541. https://
doi.org/10.1016/S0140-6736(96)07088-2
Lyles KW, Colón-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture.
N Engl J Med 357:1799–1809. https://doi.org/10.1056/NEJMo
a074941
Kanis JA, Johansson H, Odén A et al (2018) Characteristics of
recurrent fractures. Osteoporos Int 29:1747–1757. https://doi.
org/10.1007/s00198-018-4502-0
Johansson H, Siggeirsdóttir K, Harvey NC et al (2017) Imminent
risk of fracture after fracture. Osteoporos Int 28:775–780. https://
doi.org/10.1007/s00198-016-3868-0
Roux C, Fechtenbaum J, Kolta S et al (2007) Mild prevalent
and incident vertebral fractures are risk factors for new fractures. Osteoporos Int 18:1617–1624. https://doi.org/10.1007/
s00198-007-0413-1
Huntjens KM, van Geel TA, van Helden S, et al (2013) The role
of the combination of bone and fall related risk factors on shortterm subsequent fracture risk and mortality. BMC Musculoskelet
Disord 14. https://doi.org/10.1186/1471-2474-14-121
Cosman F, de Beur SJ, LeBoff MS et al (2014) Clinician’s guide
to prevention and treatment of osteoporosis. Osteoporos Int
25:2359–2381. https://doi.org/10.1007/s00198-014-2794-2
Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density
in postmenopausal women with osteoporosis. N Engl J Med
344:1434–1441. https://doi.org/10.1056/NEJM20010510344
1904
Daswani B, Desai M, Mitra S et al (2016) Influence of bone
mineral density measurement on fracture risk assessment tool®
scores in postmenopausal Indian women. Post Reprod Health
22:20–24. https://doi.org/10.1177/2053369116628722
Singh V, Pal AK, Biswas D, et al (2020) Identification of patients
at high risk of fragility fractures in an Indian clinical setting
using FRAX. Arch Osteoporos 15. https://doi.org/10.1007/
s11657-020-00807-3
Leslie WD, Shevroja E, Johansson H et al (2018) Risk-equivalent
T-score adjustment for using lumbar spine trabecular bone score
(TBS): the Manitoba BMD registry. Osteoporos Int 29:751–758.
https://doi.org/10.1007/s00198-018-4405-0
Harvey NC, Glüer CC, Binkley N et al (2015) Trabecular bone
score (TBS) as a new complementary approach for osteoporosis

13

Archives of Osteoporosis

72.

73.

74.

75.

76.

77.

78.

79.
80.
81.

82.

83.

84.
85.

86.
87.

(2021) 16:102

evaluation in clinical practice. Bone 78:216–224. https://d oi.o rg/
10.1016/j.bone.2015.05.016
Garg A, Aggarwal A, Pal R, et al (2019) Trabecular bone score
in healthy adult population of India: Chandigarh Urban Bone
Epidemiological Study (CUBES). J Endocr Soc 3. https://doi.
org/10.1210/js.2019-SAT-537
Sooragonda B, Cherian KE, Jebasingh FK, et al (2019) Longitudinal changes in bone mineral density and trabecular bone
score following yearly zoledronic acid infusion in postmenopausal osteoporosis—a retrospective-prospective study from
southern India. Arch Osteoporos 14. https://doi.org/10.1007/
s11657-019-0630-1
Kapoor N, Cherian K, Pramanik B et al (2017) Association
between dental health and osteoporosis: a study in South Indian
postmenopausal women. J Midlife Health 8:159. https://doi.org/
10.4103/jmh.JMH_21_17
Cherian KE, Kapoor N, Shetty S et al (2018) Evaluation of different screening tools for predicting femoral neck osteoporosis
in rural south Indian postmenopausal women. J Clin Densitom
21:119–124. https://doi.org/10.1016/j.jocd.2017.08.002
Satyaraddi A, Shetty S, Kapoor N, et al (2017) Performance of
risk assessment tools for predicting osteoporosis in south Indian
rural elderly men. Arch Osteoporos 12. https://doi.org/10.1007/
s11657-017-0332-5
Camacho PM, Petak SM, Binkley N et al (2016) American Association of Clinical Endocrinologists and American College of
Endocrinology clinical practice guidelines for the diagnosis and
treatment of postmenopausal osteoporosis — 2016– EXECUTIVE SUMMARY. Endocr Pract 22:1111–1118. https://doi.org/
10.4158/EP161435.ESGL
Díez-Pérez A, Marin F, Eriksen EF et al (2019) Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis. Bone 120:1–8.
https://doi.org/10.1016/j.bone.2018.09.020
Lewiecki EM (2000) Osteoporosis: clinical evaluation. In: Feingold KR, Anawalt B, Boyce A, et al (eds) Endotext. MDText.
com, Inc., South Dartmouth (MA)
Roux C, Briot K (2017) Imminent fracture risk. Osteoporos Int
28:1765–1769. https://doi.org/10.1007/s00198-017-3976-5
Leder BZ (2018) Optimizing sequential and combined anabolic
and antiresorptive osteoporosis therapy: optimizing anabolic and
antiresorptive therapy. JBMR Plus 2:62–68. https://doi.org/10.
1002/jbm4.10041
Anastasilakis AD, Papapoulos SE, Polyzos SA et al (2019) Zoledronate for the prevention of bone loss in women discontinuing
denosumab treatment. a prospective 2-year clinical trial. J Bone
Miner Res 34:2220–2228. https://doi.org/10.1002/jbmr.3853
Kendler D, Chines A, Clark P et al (2020) Bone mineral density
after transitioning from denosumab to alendronate. J Clin Endocrinol Metab 105:e255–e264. https://doi.org/10.1210/clinem/
dgz095
Lakhotia SM, Dongre P (2012) Treatment algorithm for Indian
patients of osteoporosis. Ind Med Gaz 47:67–77
Tandon V, Gillani Z, Khajuria V et al (2014) First Indian prospective randomized comparative study evaluating adherence and
compliance of postmenopausal osteoporotic patients for daily
alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates. J Midlife Health 5:29. https://doi.org/
10.4103/0976-7800.127788
File E, Deal C (2009) Clinical update on teriparatide.
Curr Rheumatol Rep 11:169–176. https://d oi.o rg/1 0.1 007/
s11926-009-0023-3
Minisola S, Cipriani C, Grotta GD, et al (2019) Update on the
safety and efficacy of teriparatide in the treatment of osteoporosis. Ther Adv Musculoskelet Dis 11:1759720X1987799. https://
doi.org/10.1177/1759720X19877994

Archives of Osteoporosis

Page 13 of 13

(2021) 16:102

88. Bhadada SK, Sridhar S, Muthukrishnan J et al (2014) Predictors
of atypical femoral fractures during long term bisphosphonate
therapy: a case series & review of literature. Indian J Med Res
140:46–54
89. Watts NB, Lewiecki EM, Bonnick SL et al (2009) Clinical value
of monitoring BMD in patients treated with bisphosphonates for
osteoporosis. J Bone Miner Res 24:1643–1646. https://doi.org/
10.1359/jbmr.090818
90. Cummings SR, Karpf DB, Harris F et al (2002) Improvement
in spine bone density and reduction in risk of vertebral fractures
during treatment with antiresorptive drugs. Am J Med 112:281–
289. https://doi.org/10.1016/S0002-9343(01)01124-X
91. Miller PD, Bilezikian JP, Deal C et al (2004) Clinical use of teriparatide in the real world: initial insights. Endocr Pract 10:139–
148. https://doi.org/10.4158/EP.10.2.139
92. Diez-Perez A, Adachi JD, Agnusdei D et al (2012) Treatment
failure in osteoporosis. Osteoporos Int 23:2769–2774. https://
doi.org/10.1007/s00198-012-2093-8
93. Miller PD (2007) Monitoring osteoporosis therapies. Curr Osteoporos Rep 5:38–43. https://doi.org/10.1007/BF02938621
94. Pal R, Agrawal K, Gupta S et al (2020) Worsening of unrecognized tumour-induced osteomalacia with inadvertent use
of recombinant human parathyroid hormone. Endokrynol Pol
71:102–103. https://doi.org/10.5603/EP.a2019.0045
95. Wu C-H, Chang Y-F, Chen C-H et al (2019) Consensus statement
on the use of bone turnover markers for short-term monitoring of

96.
97.
98.

99.
100.

102

osteoporosis treatment in the Asia-Pacific Region. J Clin Densitom. https://doi.org/10.1016/j.jocd.2019.03.004
Eastell R, Pigott T, Gossiel F et al (2018) Diagnosis of endocrine
disease: bone turnover markers: are they clinically useful? Eur J
Endocrinol 178:R19–R31. https://doi.org/10.1530/EJE-17-0585
Morris HA, Eastell R, Jorgensen NR et al (2017) Clinical usefulness of bone turnover marker concentrations in osteoporosis. Clin
Chim Acta 467:34–41. https://d oi.o rg/1 0.1 016/j.c ca.2 016.0 6.0 36
Krege JH, Lane NE, Harris JM, Miller PD (2014) PINP as a
biological response marker during teriparatide treatment for
osteoporosis. Osteoporos Int 25:2159–2171. https://doi.org/10.
1007/s00198-014-2646-0
Ro C, Cooper O (2013) Bisphosphonate drug holiday: choosing
appropriate candidates. Curr Osteoporos Rep 11:45–51. https://
doi.org/10.1007/s11914-012-0129-9
Sharma S, Tandon V, Mahajan A (2014) Bisphosphonate drug
holidays: can we recommend currently? J Midlife Health 5:111.
https://doi.org/10.4103/0976-7800.141186

Publisher’s Note Springer nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations
Sanjay K. Bhadada1 · Manoj Chadha2 · Usha Sriram3 · Rimesh Pal1 · Thomas V. Paul4 · Rajesh Khadgawat5 ·
Ameya Joshi6 · Beena Bansal7 · Nitin Kapoor4 · Anshita Aggarwal8 · Mahendra K. Garg9 · Nikhil Tandon5 ·
Sushil Gupta10 · Narendra Kotwal11 · Shriraam Mahadevan12 · Satinath Mukhopadhyay13 · Soham Mukherjee1 ·
Subhash C. Kukreja14 · Sudhaker D. Rao15 · Ambrish Mithal16
1

Department of Endocrinology, Post Graduate Institute Of
Medical Education and Research, Chandigarh 160012, India

10

Department of Endocrinology, Sanjay Gandhi Postgraduate
Institute of Medical Sciences, Lucknow 226014, India

2

Department of Endocrinology, Parmanand Deepchand
Hinduja Hospital, Mumbai 400016, India

11

Department of Endocrinology, Army Hospital Research &
Referral, New Delhi 110010, India

3

Endocrinology and Diabetology Division, Voluntary Health
Services Hospital, Chennai 600020, India

12

Endocrinology Division, Sri Ramachandra Medical Center,
Chennai 600116, India

4

Department of Endocrinology, Christian Medical College,
Vellore 632002, India

13

Department of Endocrinology, Institute of Post-Graduate
Medical Education and Research, Kolkata 700020, India

5

Department of Endocrinology, All India Institute Of Medical
Sciences, New Delhi 110023, India

14

Department of Medicine, University of Illinois, Chicago,
IL 60612, USA

6

Endocrinology Division, Bhaktivedanta Hospital,
Thane 401107, India

15

7

Endocrinology and Diabetes Division, Door to Care,
Gurgaon 122018, India

Department of Internal Medicine, Division of Endocrinology,
Diabetes and Bone & Mineral Disorders, Henry Ford, Health
System, Detroit, MI 48202, USA

16

Endocrinology and Diabetes Division, Max Healthcare,
New Delhi 110017, India

8

Department of Endocrinology, Dr. Ram Manohar Lohia
Hospital, New Delhi 110001, India

9

Department of Endocrinology, All India Institute Of Medical
Sciences, Jodhpur 342001, India

13

